Flexion Therapeutics, Inc. (NASDAQ:FLXN) has been assigned a $44.00 target price by equities research analysts at Royal Bank Of Canada in a research report issued to clients and investors on Monday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 85.19% from the stock’s current price.
A number of other research firms also recently weighed in on FLXN. Zacks Investment Research upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. ValuEngine upgraded shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Northland Securities assumed coverage on shares of Flexion Therapeutics in a research note on Thursday, August 24th. They issued an “outperform” rating and a $40.00 price target on the stock. Janney Montgomery Scott restated a “buy” rating and issued a $35.00 price target (up from $30.00) on shares of Flexion Therapeutics in a research note on Wednesday, July 12th. Finally, BMO Capital Markets restated a “buy” rating on shares of Flexion Therapeutics in a research note on Friday, August 11th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $31.50.
Flexion Therapeutics (NASDAQ FLXN) traded down 0.38% on Monday, hitting $23.67. 115,258 shares of the stock traded hands. The stock’s market cap is $755.19 million. The stock has a 50-day moving average price of $23.29 and a 200 day moving average price of $21.90. Flexion Therapeutics has a 12-month low of $15.44 and a 12-month high of $29.41.
Flexion Therapeutics (NASDAQ:FLXN) last posted its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by $0.11. On average, equities analysts expect that Flexion Therapeutics will post ($3.70) EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Flexion Therapeutics, Inc. (FLXN) Given a $44.00 Price Target by Royal Bank Of Canada Analysts” was first reported by Markets Daily and is owned by of Markets Daily. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/09/11/flexion-therapeutics-inc-flxn-given-a-44-00-price-target-by-royal-bank-of-canada-analysts.html.
In other Flexion Therapeutics news, Director Mark Stejbach acquired 1,580 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The stock was acquired at an average price of $17.02 per share, for a total transaction of $26,891.60. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 15.98% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Fiduciary Trust Co. bought a new position in Flexion Therapeutics in the 2nd quarter valued at approximately $101,000. IFP Advisors Inc raised its holdings in Flexion Therapeutics by 24.5% in the 2nd quarter. IFP Advisors Inc now owns 5,080 shares of the specialty pharmaceutical company’s stock valued at $103,000 after buying an additional 1,000 shares during the last quarter. Advisor Group Inc. raised its holdings in Flexion Therapeutics by 205.9% in the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock valued at $105,000 after buying an additional 3,500 shares during the last quarter. Voya Investment Management LLC raised its holdings in Flexion Therapeutics by 25.8% in the 2nd quarter. Voya Investment Management LLC now owns 12,914 shares of the specialty pharmaceutical company’s stock valued at $261,000 after buying an additional 2,651 shares during the last quarter. Finally, BB&T Securities LLC bought a new position in Flexion Therapeutics in the 2nd quarter valued at approximately $289,000. Institutional investors and hedge funds own 82.75% of the company’s stock.
Flexion Therapeutics Company Profile
Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.
Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.